ProMIS Neurosciences Inc PMN

Pharma companies should be lining up to partner with us

[JoeyBoston]

Today's decision was huge as it gave the green light to invest in the amyloid hypothesis to fight AD. All players in this space, not just Biogen, went up big including Eli Lilly.

Seems like big pharma would be lining up to partner with or buy-out/merge with Promis. Throw in Cashman's platform and how that is working to combat Covid, and this company has to be worth a few Billion today or in the near fiture.

[Mole101]

I would just be happy with Biogen deciding to throw some cash at us for a little piece of the pie, it would make sense to try to improved their product and PMN could be the solution ( I'm just dreaming) ..but I would be happy with any partnerships   

[JoeyBoston]

Do we have to wait for the new CEO before a partnership happens? How close do you think we are in getting one? 

[retiredcop]

Maybe .lets allow everyone to  digest what's actually happened with Biogen...the next few days we will see if the nay sayers have changed their outlook now that Biogen got  approval with no real conditions on what stage ad suffers could access the treatment. This no cavetes approval actually surprised people in PMN..and I think there are a lot of really happy people at PMN, 

[Mole101]

There is real money to be made and that will attract partnerships if they see potencial and revenues .. The FDA said it will continue to monitor the drug as it reaches the U.S. market. The agency granted approval on the condition that Biogen conduct another clinical trial. The Massachusetts-based biotechnology company said Monday that aducanumab's list price is $56,000 per year; $4,312 per

[Gbathat]

Management has been telling us for well over a year that Phase 1 funding for PMN310 is contingent on aducanumab approval, or at least that the delays in aducanumab approval were delaying investment in PMN310. I would be shocked if they do not have a plan for capitalizing on the news today, given that they have been leading the cheers for Biogen through multiple PRs and commentaries.  PMN

[goldtech]

Yes the majors will be at the door and we need a deal maker here not Elliott or Gene who have only taken money and shares for nothing. The logical choice for any major is to joint venture with someone who is ready to go clinical. Remember it takes years to go through the animal models, shoe efficacy and specificity and side effects. We are years ahead and very attractive. This will happen fast and

[Gbathat]

I think the only thing between PMN and that multi-billion dollar valuation is a big partner or a funded PhI.  A big partner would be better long term, especially if it involved future revenue splits instead of just ownership. I still think Zack's small cap analyst John Vandermosten's valuation of $5 per share was pretty reasonable given the market size and strong technical case for